co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Dishman Pharmaceuticals and Chemicals' subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company. The acquisition, he says, is funded trough internal accruals.
In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.
In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.
VVS Murthy, CFO of Dishman Pharma, in an interview with CNBC-TV18's Latha Venkatesh and Gautam Broker, spoke about the recent report by one of the brokerages Indiabulls Securities, which downgraded the company's stocks and the road ahead.
Dishman Pharma has reported a consolidated net profit of Rs 1.7 crore for the quarter ended December 2010 as against Rs 33 crore in same quarter, the previous year. The company's consolidated net sales increased to Rs 230 crore from Rs 220 crore (YoY).
